The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus: A model of medicine- based evidence

European Journal of Clinical Pharmacology

Volumn 55, Issue 4, 1999, Pages 239-249

  Scorpiglione, N ^a   Belfiglio, M ^a   Carinci, F ^a   Cavaliere, D ^a   De Curtis, A ^a   Franciosi, M ^a   Mari, E ^a   Sacco, M ^a   Tognoni, G ^a   Nicolucci, A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Acarbose; Evidence based medicine; Type II diabetes mellitus

Indexed keywords

ACARBOSE; GLUCOSE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACARBOSE; AGED; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; ITALY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; TRISACCHARIDES;

EID: 0032912970     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050623     Document Type: Article

References (28)

1. 1. Lee B (1992) The costs of diabetes and its complications. Soc Sci Med 35: 1303-1310
2. 2. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA (1989) The economic costs of non-insulin-dependent diabetes mellitus. JAMA 262: 2708-2713
3. 3. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986
4. 4. Clissold SP, Edwards C (1988) Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35: 214-243
5. 5. Dimitriadis G, Karaiskos C, Raptis S (1986) Effect of prolonged (6 months) α-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 18: 253-255
6. 6. Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G (1991) Double-blind crossover study of acarbose in type I diabetic patients. Diabet Med 8: 674-678
7. 7. Hollander P, Pi-Sunyer X, Coniff RF (1997) Acarbose in the treatment of type I diabetes. Diabetes Care 20: 248-253
8. 8. Johansen K (1984) Acarbose treatment of sulfonylurea-treated non-insulin-dependent diabetics. Diabetes Metab 10: 219-223
9. 9. Buchanan DR, Collier A, Rodrigues E, Millar AM, Gray RS, Clarke BF (1988) Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin-dependent diabetes. Eur J Clin Pharmacol 34: 51-53
10. 10. Rodier M, Richard JL, Monnier L, Mirouze J (1988) Effect of long-term acarbose (BAY g 5421) therapy on metabolic control of non-insulin-dependent (type II) diabetes mellitus. Diabetes Metab 14: 12-14
11. 11. Rao RH, Spathis GS (1990) α-Glucosidase inhibitor therapy does not improve glycaemic control in overweight diabetics poorly controlled on sulfonylureas. Diab Nutr Metab 3: 17-22
12. 12. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fuker K (1991) Therapeutic potentials of acarbose as a first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732-737
13. 13. Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazaua S, Sakamoto N (1993) Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 10: 134-138
14. 14. Santeusanio F, Ventura MM, Contadini S, Compagnucci P, Moriconi V, Zaccarini P, Marra G, Amigoni S, Bianchi W, Brunetti P (1993) Efficacy and safety of two different dosages of acarbose in non-insulin-dependent diabetic patients treated by diet alone. Diab Nutr Metab 6: 147-154
15. 15. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, D'Embden E (1993) Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 16: 499-502
16. 16. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS (1994) The efficacy of acarbose in the treatment of non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928-935
17. 17. Hoffmann J, Spengler M (1994) Efficacy of 24-week mono-therapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 17: 561-566
18. 18. Coniff RF, Shapiro JA, Seaton TB (1994) Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 154: 2442-2448
19. 19. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA (1995) A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18: 928-932
20. 20. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB (1995) Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18: 817-824
21. 21. Coniff RF, Shapiro JA, Seaton TB, Bray GA (1995) Multi-center, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98: 443-451
22. 22. Bayraktar M, Van Thiel DH, Adalar N (1996) A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19: 252-254
23. 23. Balfour JA, McTavish D (1993) Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 46: 1025-1054
24. 24. Zeger SL, Liang KY (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121-130
25. 25. Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures on the consequences of treatment. N Engl J Med 318: 1728-1733
26. 26. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
27. 27. American Diabetes Association (1998) Standards of medical care for patients with diabetes mellitus. Diabetes Care 2 [Suppl 1]: S23-S31
28. 28. Knottnerus JA, Dinant GJ (1997) Medicine based evidence, a prerequisite for evidence based medicine. BMJ 315: 1109-1110